HIGHBuilt-in & outside partyProduct / Revenue mix
PEDMARK
“10-K Item 1A: 'we expect that all of our product revenues in the foreseeable future will be from sales of PEDMARK®'”
FENC · Concentration risk · 10-K extracted
Fennec Pharmaceuticals (FENC) concentration risks
Updated
The most significant concentration Fennec Pharmaceuticals discloses is PEDMARK, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Fennec Pharmaceuticals’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 4 disclosed concentrations
HIGH3
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
third-party contract manufacturer (PEDMARK)
“10-K Item 1A: 'deficiencies in the third-party manufacturing facility that manufactures PEDMARK® on our behalf is a specific example of the risks associated with our third-party manufacturers'”
HIGHOutside partySupplier
exclusive specialty pharmacies
“10-K Item 1A: 'we are using a very small group of exclusive specialty pharmacies to distribute our product'”
MEDIUMOutside partyCounterparty
Norgine
“10-K Item 1A: 'Our international commercialization strategy depends on collaborative relationships with our third party development partners, including Norgine in Europe'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-08-23Fennec Pharmaceuticals presents a concentrated risk profile built entirely around a single product. The company expects all of its product revenues in the foreseeable future to come from sales of PEDMARK®, a high-share, mixed-character exposure — mixed because a single-product revenue base is both the entire growth story and the single point of failure. That concentration cascades into the supply chain: PEDMARK is manufactured by a third-party contract manufacturer, a high-share dependency, and any deficiency at that facility becomes an immediate operational risk given there is no diversified manufacturing base to fall back on. Distribution carries the same structure — the company relies on a very small group of exclusive specialty pharmacies, another high-share dependency, meaning a disruption at even one distribution partner could constrain access to the only product driving revenue. A further dependency sits with Norgine, the company's international commercialization partner in Europe, a medium-share exposure that extends collaborative-relationship risk into international markets. None of these exposures carries a disclosed percentage, but together they show that PEDMARK's product, manufacturing, and distribution chain form one tightly linked risk rather than several independent ones — a disruption anywhere along it directly threatens the whole revenue base.
For the engine’s reasoning on FENC’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| FENC● | Fennec Pharmaceuticals Inc. | 3 | 1 | 0 | 4 |
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.